| Sep 13 |
Johnson & Johnson: A Strategic MedTech Shift For This Dividend King
|
| Sep 12 |
JNJ submits application to EMA for nipocalimab for generalized myasthenia gravis
|
| Sep 12 |
FDA Grants Label Expansion to J&J's Tremfya in Ulcerative Colitis
|
| Sep 12 |
How To Earn $500 A Month From Johnson & Johnson Stock
|
| Sep 12 |
J&J Tremfya label expanded in the U.S. for inflammatory bowel disease
|
| Sep 12 |
FDA approves Johnson & Johnson’s TREMFYA for ulcerative colitis
|
| Sep 12 |
Is Johnson & Johnson (JNJ) the Best Defensive Stock According to Reddit?
|
| Sep 11 |
TREMFYA® (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel disease
|
| Sep 11 |
J&J mid-stage trial for lung cancer drug Rybrevant hits main goal
|
| Sep 11 |
J&J leads $50M financing for imaging company Spectrawave
|
